Suppr超能文献

多囊卵巢综合征、复方口服避孕药与血糖异常风险:一项基于人群的队列研究及巢式药物流行病学病例对照研究。

Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study.

机构信息

Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, U.K.

Department of Community and Family Medicine, Faculty of Medicine, University of Jaffna, Kokkuvil, Sri Lanka.

出版信息

Diabetes Care. 2021 Dec;44(12):2758-2766. doi: 10.2337/dc21-0437. Epub 2021 Oct 14.

Abstract

OBJECTIVE

Irregular menstrual cycles are associated with increased cardiovascular mortality. Polycystic ovary syndrome (PCOS) is characterized by androgen excess and irregular menses; androgens are drivers of increased metabolic risk in women with PCOS. Combined oral contraceptive pills (COCPs) are used in PCOS both for cycle regulation and to reduce the biologically active androgen fraction. We examined COCP use and risk of dysglycemia (prediabetes and type 2 diabetes) in women with PCOS.

RESEARCH DESIGN AND METHODS

Using a large U.K. primary care database (The Health Improvement Network [THIN]; 3.7 million patients from 787 practices), we carried out a retrospective population-based cohort study to determine dysglycemia risk (64,051 women with PCOS and 123,545 matched control subjects), as well as a nested pharmacoepidemiological case-control study to investigate COCP use in relation to dysglycemia risk (2,407 women with PCOS with [case subjects] and without [control subjects] a diagnosis of dysglycemia during follow-up). Cox models were used to estimate the unadjusted and adjusted hazard ratio, and conditional logistic regression was used to obtain adjusted odds ratios (aORs).

RESULTS

The adjusted hazard ratio for dysglycemia in women with PCOS was 1.87 (95% CI 1.78-1.97, < 0.001; adjustment for age, social deprivation, BMI, ethnicity, and smoking), with increased rates of dysglycemia in all BMI subgroups. Women with PCOS and COCP use had a reduced dysglycemia risk (aOR 0.72, 95% CI 0.59-0.87).

CONCLUSIONS

In this study, limited by its retrospective nature and the use of routinely collected electronic general practice record data, which does not allow for exclusion of the impact of prescription-by-indication bias, women with PCOS exposed to COCPs had a reduced risk of dysglycemia across all BMI subgroups. Future prospective studies should be considered for further understanding of these observations and potential causality.

摘要

目的

不规律的月经周期与心血管死亡率的增加有关。多囊卵巢综合征(PCOS)的特征是雄激素过多和月经不规律;雄激素是 PCOS 女性代谢风险增加的驱动因素。复方口服避孕药(COCP)既用于调节周期,也用于降低生物活性雄激素部分。我们研究了 COCP 的使用与 PCOS 女性的血糖异常(糖尿病前期和 2 型糖尿病)风险。

研究设计和方法

使用英国大型初级保健数据库(健康改善网络[THIN];来自 787 个实践的 370 万患者),我们进行了一项回顾性基于人群的队列研究,以确定血糖异常风险(64051 名 PCOS 患者和 123545 名匹配的对照受试者),以及嵌套的药物流行病学病例对照研究,以调查 COCP 使用与血糖异常风险的关系(2407 名 PCOS 患者,在随访期间患有[病例组]或不患有[对照组]血糖异常的诊断)。Cox 模型用于估计未调整和调整后的危险比,条件逻辑回归用于获得调整后的优势比(aOR)。

结果

PCOS 女性的血糖异常调整后的危险比为 1.87(95%CI 1.78-1.97,<0.001;调整年龄、社会剥夺、BMI、种族和吸烟因素),所有 BMI 亚组的血糖异常发生率均增加。使用 COCP 的 PCOS 女性血糖异常风险降低(aOR 0.72,95%CI 0.59-0.87)。

结论

在这项研究中,由于其回顾性性质和使用常规收集的电子一般实践记录数据的限制,这不能排除处方指征偏差的影响,暴露于 COCP 的 PCOS 女性在所有 BMI 亚组中血糖异常的风险降低。应考虑进行未来的前瞻性研究,以进一步了解这些观察结果和潜在的因果关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5b3/8669537/a37c1d914a95/dc210437f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验